U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07480863) titled 'Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL' on March 14.
Brief Summary: In patients with previously untreated Marginal zone lymphoma (MZL), a treatment regimen of Orelabrutinib,Zuberitamab combined with Cyclophosphamide,Vincristine,Prednisoneacetatetablets is planned to be used.
Study Start Date: Oct. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Marginal Zone Lymphoma(MZL)
Intervention:
DRUG: Orelabrutinib
After the patient received one cycle of the anti-CD20 monoclonal antibody CVP regimen, obinutuzumab was added starting from the second cycle for combination therapy. After a total of five cycles of the...